FDA Approves Orforglipron For Chronic Weight Management

The FDA approved orforglipron (Foundayo) as the first new molecular entity to be cleared under the Commissioner's National Priority Voucher (CNPV) pilot program. This milestone decision was reached 50 days after filing, coming 294 days before its scheduled Prescription Drug User Fee Act date and marking the fastest approval of a new molecular entity since 2002.¹

Developed by Eli Lilly and Company, orforglipron is indicated for chronic weight management in adults with obesity or those who are overweight with at least 1 weight-related comorbid condition, used as an adjunct to a reduced-calorie diet and increased physical activity. For pharmacists, the clinical significance of this approval lies in the drug's unique pharmacokinetic profile as a nonpeptide, oral glucagon-like peptide-1 (GLP-1) receptor agonist.

“This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners,” FDA Commissioner Martin Makary, MD, MPH, said in a news release. “By cutting idle time and maintaining constant communications with the company throughout the review process, we completed this national priority review with outstanding efficiency while upholding the FDA’s gold-standard science. This reflects the level of performance the public should expect from the FDA.”

Orforglipron does not require the strict fasting or water intake protocols associated with current oral GLP-1 peptide therapies. Because it is a nonpeptide small molecule, patients can take the once-daily tablet at any time of day without food or water restrictions. The recommended starting dosage is 0.8 mg, which should be titrated upward in 30-day intervals to 2.5 mg and then 5.5 mg. Depending on treatment response and patient tolerability, pharmacists may see further dose increases to 9 mg, 14.5 mg, or 17.2 mg after at least 30 days at each level.^1,2

Clinical trial data from the ACHIEVE program further distinguish orforglipron’s efficacy relative to existing treatments. In the head-to-head ACHIEVE-3 (NCT06045221) trial, a 36 mg dose of orforglipron demonstrated clinically meaningful superiority over oral semaglutide, achieving a 2.2% reduction in A_1C compared with 1.4% with 14 mg of semaglutide.²

Furthermore, orforglipron led to an average weight loss of 19.7 pounds, a result that was nearly 74% greater than the weight loss seen in the semaglutide cohort. Beyond weight and glycemic control, the data highlight that orforglipron improved other cardiometabolic risk factors, including systolic blood pressure, triglycerides, and nonhigh-density lipoprotein cholesterol.

Pharmacists should also be aware of the medication’s role in long-term maintenance for patients transitioning from injectable therapies. Data from the ATTAIN-MAINTAIN (NCT06584916) trial showed that orforglipron effectively sustained weight reduction in patients switching directly from the highest tolerated doses of injectable semaglutide or tirzepatide. This suggests a potential future role for the drug as a convenient oral maintenance option for those who have already achieved initial weight loss through injectables.³

In other phase 3 studies, specifically ACHIEVE-2 (NCT06192108) and ACHIEVE-5 (NCT06109311), the drug also outperformed dapagliflozin and showed significant efficacy as an adjunct to titrated basal insulin.⁴

From a safety perspective, orforglipron carries a boxed warning for thyroid C-cell tumors, and it is contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Consistent with the GLP-1 receptor agonist class, the most frequent adverse events are gastrointestinal, including nausea, constipation, diarrhea, and vomiting.^1-3

Other reported adverse effects include hair loss, dyspepsia, and fatigue, while the labeling contains precautions regarding pancreatitis, acute kidney injury, and hypoglycemia. Pharmacists must advise patients that orforglipron should not be used in combination with any other GLP-1 receptor agonist.¹

“Individuals who are overweight or obese now have an additional option to help with weight loss—a GLP-1 receptor partial agonist pill, which does not need to be taken on an empty stomach,” Acting Center for Drug Evaluation and Research (CDER) Director Tracy Beth Høeg, MD, PhD, said in the news release. “The CDER review team delivered a thorough, high-quality product review and benefit-risk analysis while simultaneously taking months off the standard filing-to-decision time.”

READ MORE: Obesity Management Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips straight to your inbox.

REFERENCES

1. FDA approves first new molecular entity under national priority voucher program. News release. FDA. April 1, 2026. Accessed April 1, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program

2. Gallagher A. Orforglipron demonstrates superior blood sugar control compared with oral semaglutide. Drug Topics. February 26, 2026. Accessed April 1, 2026. https://www.drugtopics.com/view/orforglipron-demonstrates-superior-blood-sugar-control-compared-with-oral-semaglutide

3. Gallagher A. Orforglipron maintains weight loss after discontinuation of injectable GLP-1. Drug Topics. January 3, 2026. Accessed April 1, 2026. https://www.drugtopics.com/view/orforglipron-maintains-weight-loss-after-discontinuation-of-injectable-glp-1

4. Gallagher A. Orforglipron demonstrates superior glycemic control for type 2 diabetes. Drug Topics. October 16, 2025. Accessed April 1, 2026. https://www.drugtopics.com/view/orforglipron-demonstrates-superior-glycemic-control-for-type-2-diabetes